Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRT-232 or TL-895 in JAKi-Naïve Myelofibrosis
NCT04878003Phase 2Recruiting
- Sponsor
- Kartos Therapeutics
- Start
- Apr 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of navtemadlin, TL-895 in myelofibrosis (MF), sponsored by Kartos Therapeutics. Started Apr 2021; status: recruiting.
02
Drugs
navtemadlinTL-895
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04878003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878003.